TY - JOUR AU - Venere, Monica PY - 2017 TI - Getting down to the FACT: therapeutic targeting of MYC -dependent tumors JF - Annals of Translational Medicine; Vol 5, No 7 (April 14, 2017): Annals of Translational Medicine Y2 - 2017 KW - N2 - The MYC oncogene is thought to be involved in more than half of all human tumors and hence has great potential as a targeted therapy. However, despite the well appreciated role of oncogenes in the pathogenesis and maintenance of tumors, the ability to directly target them has proven elusive save a few examples, such as imatinib for chronic myelogenous leukemia. Recently, Carter et al. reported a way to circumvent the necessity to directly target MYC in neuroblastoma, a MYC -driven pediatric cancer, by identifying a downstream factor that was essential for the high expression of MYC -targeted genes in these tumors (1). UR - https://atm.amegroups.org/article/view/14034